drugset / Trial / NCT00164242

Treatment of Tardive Dyskinesia With Galantamine

NCT00164242

RandomizedCrossoverDouble-blindTreatment

Summary

Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we conducted a 30-week randomized, double-blind, placebo-controlled crossover study of galantamine in 36 patients with TD.

Timeline

Start
2002-01
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 12 mg

Indications